Nov. 2, 2010 – Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government’s Qualifying Therapeutic Discovery Project (QTDP) program.The $94,836 grant will assist Synergenz’s ongoing clinical utility trials for Respiragene™, a genetic-based test for lung cancer predisposition. Respiragene™ identifies the subset of individuals most likely to develop lung cancer from their smoking habit -- before disease strikes -- allowing doctors to improve preventative care for a cancer usually diagnosed too late to save their patients... Synergenz's Press Release -
